Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil + Pembrolizumab in Advanced Melanoma
NCT02574533Phase 1Completed
- Sponsor
- Gradalis, Inc.
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemogenovatucel-T in melanoma, sponsored by Gradalis, Inc. Primary endpoint: Tumor Immune-Related Response to Vigil and Vigil + Pembrolizumab at 16 weeks. Started Oct 2015; status: completed.
02
Drugs
gemogenovatucel-T
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02574533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574533.